Bicara Therapeutics Inc. reports durable responses for ficerafusp alfa plus pembrolizumab in HPV negative HNSCC

Bicara Therapeutics Inc. reports durable responses for ficerafusp alfa plus pembrolizumab in HPV negative HNSCC
Bicara posts trial results

Bicara Therapeutics Inc. released newly published data in the Journal of Clinical Oncology showing clinical outcomes for the combination of ficerafusp alfa and pembrolizumab in first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC).

A more extensive analysis of the data points to deep and lasting responses, as well as promising survival results, particularly in a patient population with high unmet medical needs. The findings may signal a step forward in targeted treatment strategies for these challenging cases.

Bicara Therapeutics is set to present its first quarter 2026 financial results and business update on May 11 via a public webcast, according to a recent announcement. The scheduled event follows ongoing efforts by the company to advance its product pipeline. The company has not provided further details on its upcoming financial disclosures.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.